Castleview Partners LLC Sells 151 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Castleview Partners LLC cut its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 10.4% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,294 shares of the medical research company’s stock after selling 151 shares during the quarter. Castleview Partners LLC’s holdings in Thermo Fisher Scientific were worth $644,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in TMO. PFG Investments LLC lifted its position in shares of Thermo Fisher Scientific by 4.0% during the 1st quarter. PFG Investments LLC now owns 2,222 shares of the medical research company’s stock valued at $1,106,000 after acquiring an additional 86 shares during the period. Canoe Financial LP bought a new stake in shares of Thermo Fisher Scientific during the 1st quarter valued at $3,981,000. Rockline Wealth Management LLC lifted its position in shares of Thermo Fisher Scientific by 9.2% during the 1st quarter. Rockline Wealth Management LLC now owns 1,669 shares of the medical research company’s stock valued at $830,000 after acquiring an additional 140 shares during the period. Covea Finance lifted its position in shares of Thermo Fisher Scientific by 3.9% during the 1st quarter. Covea Finance now owns 103,114 shares of the medical research company’s stock valued at $51,310,000 after acquiring an additional 3,913 shares during the period. Finally, Walter & Keenan Wealth Management LLC IN ADV lifted its position in shares of Thermo Fisher Scientific by 9.8% during the 1st quarter. Walter & Keenan Wealth Management LLC IN ADV now owns 878 shares of the medical research company’s stock valued at $437,000 after acquiring an additional 78 shares during the period. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In related news, EVP Gianluca Pettiti sold 300 shares of the company’s stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $429.93, for a total transaction of $128,979.00. Following the sale, the executive vice president now owns 23,167 shares in the company, valued at $9,960,188.31. This represents a 1.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.33% of the stock is owned by corporate insiders.

Thermo Fisher Scientific Trading Up 1.2%

Shares of TMO stock opened at $397.31 on Friday. The stock has a market cap of $149.98 billion, a price-to-earnings ratio of 23.30, a PEG ratio of 2.07 and a beta of 0.78. The stock has a 50-day moving average of $412.62 and a 200-day moving average of $487.84. The company has a current ratio of 1.77, a quick ratio of 1.38 and a debt-to-equity ratio of 0.64. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $627.88.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, beating the consensus estimate of $5.10 by $0.05. The company had revenue of $10.36 billion during the quarter, compared to analysts’ expectations of $10.23 billion. Thermo Fisher Scientific had a return on equity of 17.15% and a net margin of 15.19%. The business’s quarterly revenue was up .2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $5.11 earnings per share. On average, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, July 15th. Stockholders of record on Friday, June 13th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, June 13th. This represents a $1.72 annualized dividend and a dividend yield of 0.43%. Thermo Fisher Scientific’s payout ratio is 10.09%.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on TMO. Wall Street Zen upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research report on Wednesday, May 21st. Scotiabank lowered their price target on Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a report on Friday, April 25th. The Goldman Sachs Group set a $610.00 price target on Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Wednesday, April 23rd. Robert W. Baird lowered their price target on Thermo Fisher Scientific from $603.00 to $573.00 and set an “outperform” rating for the company in a report on Thursday, April 24th. Finally, UBS Group lowered their price target on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating for the company in a report on Thursday, April 24th. Four research analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $605.30.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.